• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PRQR

    ProQR Therapeutics N.V.

    Subscribe to $PRQR
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

    IPO Year: 2014

    Exchange: NASDAQ

    Website: proqr.com

    Recent Analyst Ratings for ProQR Therapeutics N.V.

    DatePrice TargetRatingAnalyst
    4/29/2025$5.00Outperform
    Evercore ISI
    4/29/2025$8.00Overweight
    Cantor Fitzgerald
    3/10/2025$4.00Neutral → Buy
    Citigroup
    1/10/2025$15.00Outperform
    Oppenheimer
    10/29/2024$6.00 → $14.00Outperform → Strong Buy
    Raymond James
    11/8/2023$2.00Neutral → Buy
    Chardan Capital Markets
    3/30/2023$1.50 → $5.00Mkt Perform → Mkt Outperform
    JMP Securities
    12/22/2022$0.80 → $5.00Neutral → Overweight
    Cantor Fitzgerald
    2/14/2022$18.00 → $8.00Buy
    Chardan Capital
    2/14/2022$37.00 → $1.70Buy → Neutral
    Citigroup
    See more ratings